Clinical trial · no report yet · Phase 3
EMBER-3
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
- NCT04975308 ↗
- Active, not recruiting
- Eli Lilly and Company
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 138 | |
| YouTube | 129 | |
| Podcasts | 89 | |
| Bluesky threads | 2 | |
| X videos | 2 |
The trial
ClinicalTrials.gov- Official title
- EMBER-3: A Phase 3, Randomized, Open-Label Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Patients With Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With Endocrine Therapy
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Breast Neoplasms; Neoplasm Metastasis
- Interventions
- Imlunestrant; Exemestane; Fulvestrant; Abemaciclib
- Arms
- Arm A: Imlunestrant · Experimental
- Arm B: Investigator's Choice of Endocrine Therapy · Experimental
- Arm C: Imlunestrant + Abemaciclib · Experimental
- Enrollment
- 874
- Primary outcomes
- Investigator-assessed Progression Free Survival (PFS) (Between Arm A and Arm B)
- Investigator-assessed PFS (Between Arm C and Arm A)
- Investigator-assessed PFS in the Estrogen Receptor 1 (ESR1)-Mutation Detected Population (Between Arm A and Arm B)
- Sponsor
- Eli Lilly and Company
- Start
- Oct 4, 2021
- Primary completion
- Jun 24, 2024
- Results posted
- Yes
- Registry record
- NCT04975308 · updated Jul 22, 2026
Publications
linked from the registry- Jhaveri KL, Neven P, Casalnuovo ML, Kim SB, Tokunaga E, Aftimos P, Saura C, O'Shaughnessy J, Harbeck N, Carey LA, Curigliano G, Llombart-Cussac A, Lim E, Garcia Tinoco ML, Sohn J, Mattar A, Zhang Q, Huang CS, Hung CC, Martinez Rodriguez JL, Ruiz Borrego M, Nakamura R, Pradhan KR, Cramer von Laue C, Barrett E, Cao S, Wang XA, Smyth LM, Bidard FC; EMBER-3 Study Group. Imlunestrant with or without Abemaciclib in Advanced Breast Cancer. N Engl J Med. 2025 Mar 27;392(12):1189-1202. doi: 10.1056/NEJMoa2410858. Epub 2024 Dec 11. PubMed 39660834